Running Claude Code locally is easy. All you need is a PC with high resources. Then you can use Ollama to configure and then ...

COBOL is in the headlines again, and this time it is because of artificial intelligence (AI) – sparking conversations with tools emerging that claim t.

While Anthropic’s Claude Code grabbed headlines, IBM has been deploying its own generative AI solution, Watsonx Code Assistant for Z, designed to modernize the very mainframes it built. Unlike general ...

Investors wiped $40 billion from IBM's market cap after Anthropic released COBOL translation tools. Analysts say the market ...

IBM’s ( IBM) Software and Chief Commercial Officer, Rob Thomas, wrote in a Monday blog post that translating COBOL code isn’t equivalent to modernizing enterprise systems, emphasizing that platform ...

The drive towards newer Java versions and updated enterprise specifications isn’t just about keeping up with the latest tech; ...

News from the week beginning February 9th includes @CybageSoftware, @Deel, @Expereo, @Freshworks, @NetSuite, @Nintex, @Panasonic, @Percona, @ThomsonReuters,@ WSO2, @Zoho ...

More and more organisations are using Java as foundational language for AI development, with Azul’s 2026 State of Java Survey & Report revealing a significant increase. Last year’s report showed 50% ...

Email notifications are only sent once a day, and only if there are new matching items. Advocates of Navajo Code Talkers — U.S. Marines in World War II who relayed critical messages in secret, ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Fullerton has launched its new city-operated ambulance transportation program. Under the model, fire personnel will manage the full emergency response, from initial patient contact to transport to a ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.